Skip to main content
[Preprint]. 2024 Feb 28:rs.3.rs-3956671. [Version 1] doi: 10.21203/rs.3.rs-3956671/v1

Figure 5. Clinical relevance of tumor antigen reactive, KIR+CD8+ T cells.

Figure 5

A) Table of clinical and surface protein-encoding genes selected by the Lasso Logistic model to classify circulating CD8+ T cells as tumor antigen reactive, KIR+CD8+ T cells (left). Receiver-operating curves summarizing the predictive accuracy of the Lasso Logistic model classifier in the immunotherapy-naive (center) and immunotherapy-resistant cohorts (right). B) Three-year overall survival based on a high (> median) or low (≤ median) frequency of tumor antigen reactive, KIR+CD8+ T cells identified using the Lasso Logistic model classifier in patients with advanced melanoma (n = 29) and C) the patients previously resistant to immunotherapy (n = 12). D) Three-year overall survival based on a high (> median) or low (< median) frequency of the tumor antigen reactive, KIR+CD8+ T cells in the flow cytometry cohort (n = 47). Between group differences are measured by Gehan-Breslow-Wilcoxon test (p < 0.05).